Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of human immunodeficiency virus (HIV) type 1 envelope in the anti-HIV activity of the betulinic acid derivative IC9564.

Antimicrobial agents and chemotherapy - 1 Jan 2001

Holz-Smith S L, Sun I C, Jin L, Matthews T J, Lee K H, Chen C H

Abstract excerpt

The betulinic acid derivative IC9564 is a potent anti-human immunodeficiency virus (anti-HIV) compound that can inhibit both HIV primary isolates and laboratory-adapted strains. However, this compound did not affect the replication of simian immunodeficiency virus and respiratory syncytial virus. Results from a syncytium formation assay indicated that IC9564 blocked HIV type 1 (HIV-1) envelope-mediated membrane...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Cell Fusion

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Microbial

Share to HIV Envelope Protein gp120

Share to HIV Envelope Protein gp41

Share to Mutagenesis

Share to T-Lymphocytes

Share to Triterpenes

Source

Open in PubMed Open full text

Identifiers

PMID: 11120945
DOI: 10.1128/AAC.45.1.60-66.2001
PMCID: PMC90240

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of human immunodeficiency virus (HIV) type 1 envelope in the anti-HIV activity of the betulinic acid derivative IC9564.PMID 11120945Read ↗

Synthesis of betulinic acid derivatives as entry inhibitors against HIV-1 and bevirimat-resistant HIV-1 variantsSemantic proximity Read ↗

Localized Changes in the gp120 Envelope Glycoprotein Confer Resistance to Human Immunodeficiency Virus Entry Inhibitors BMS-806 and #155Semantic proximity Read ↗

The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication.Semantic proximity Read ↗

Sensitivity of human immunodeficiency virus to bicyclam derivatives is influenced by the three-dimensional structure of gp120.Semantic proximity Read ↗

Bifunctional Anti-Human Immunodeficiency Virus Type 1 Small Molecules with Two Novel Mechanisms of ActionSemantic proximity Read ↗

Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.Semantic proximity Read ↗

A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor bindingSemantic proximity Read ↗

A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41.Semantic proximity Read ↗

Novel Approaches to Inhibit HIV EntrySemantic proximity Read ↗

HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug.Semantic proximity Read ↗

N-Substituted Pyrrole Derivatives as Novel Human Immunodeficiency Virus Type 1 Entry Inhibitors That Interfere with the gp41 Six-Helix Bundle Formation and Block Virus FusionSemantic proximity Read ↗

Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.